As ABCG2 has previously been shown to be critical for ALA-PDT in different human cancers, including brain and colorectal cancers [17,18,19], inhibition of ABCG2 could potentially enhance the efficacy of ALA-PDT in treatment of HNC. This evidence concerns the gene ABCG2 and colorectal cancer.